Huakang Biomedical Holdings マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Chunguang Zhang

最高経営責任者

CN¥703.0k

報酬総額

CEO給与比率	44.7%
CEO在任期間	7.3yrs
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	4.5yrs

経営陣の近況

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

CEO報酬分析

Huakang Biomedical Holdings の収益と比較して、Chunguang Zhang の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-CN¥6m
Mar 31 2024	n/a	n/a	-CN¥6m
Dec 31 2023	CN¥703k	CN¥314k	-CN¥6m
Sep 30 2023	n/a	n/a	-CN¥5m
Jun 30 2023	n/a	n/a	-CN¥4m
Mar 31 2023	n/a	n/a	-CN¥3m
Dec 31 2022	CN¥689k	CN¥308k	-CN¥3m
Sep 30 2022	n/a	n/a	-CN¥2m
Jun 30 2022	n/a	n/a	-CN¥3m
Mar 31 2022	n/a	n/a	-CN¥4m
Dec 31 2021	CN¥399k	CN¥271k	-CN¥4m
Sep 30 2021	n/a	n/a	-CN¥7m
Jun 30 2021	n/a	n/a	-CN¥8m
Mar 31 2021	n/a	n/a	-CN¥10m
Dec 31 2020	CN¥727k	CN¥250k	-CN¥12m
Sep 30 2020	n/a	n/a	-CN¥9m
Jun 30 2020	n/a	n/a	-CN¥7m
Mar 31 2020	n/a	n/a	-CN¥3m
Dec 31 2019	CN¥349k	CN¥227k	-CN¥284k
Sep 30 2019	n/a	n/a	-CN¥3m
Jun 30 2019	n/a	n/a	-CN¥2m
Mar 31 2019	n/a	n/a	-CN¥377k
Dec 31 2018	CN¥284k	CN¥234k	-CN¥459k
Dec 31 2017	CN¥243k	CN¥183k	-CN¥2m

報酬と市場: Chunguangの総報酬 ($USD 96.99K ) は、 Hong Kong市場 ($USD 232.62K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Chunguangの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Chunguang Zhang (56 yo)

7.3yrs

在職期間

CN¥703,000

報酬

Mr. Chunguang Zhang is Chief Executive officer at Huakang Biomedical Holdings Company Limited. Mr. Zhang is mainly responsible for business operations and the day-to-day management of Group. Mr. Zhang has...

取締役

名称	ポジション	在職期間	報酬	所有権
Shuguang Zhang	Chairman of the Board	7.3yrs	CN¥479.00k	27.71% HK$ 22.2m
Chunguang Zhang	CEO & Executive Director	7.3yrs	CN¥703.00k	データなし
Lai Yin Poon	CFO, Compliance Officer & Executive Director	7.3yrs	CN¥769.00k	0.80% HK$ 640.0k
Jiaming He	Business Development Director & Executive Director	4.8yrs	CN¥484.00k	データなし
Faat Ting Cheng	Independent Non Executive Director	4.2yrs	CN¥90.00k	データなし
Yim Yang Chang	Vice Chairman of King Grace Company Limited	no data	データなし	データなし
Ming Xu	Non-Executive Director	less than a year	データなし	データなし
Kwok Fai Chow	Independent Non-Executive Director	3.9yrs	CN¥90.00k	データなし
Ching Man Chow	Independent Non-Executive Director	1.3yrs	CN¥38.00k	データなし

4.5yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: 8622の取締役会は経験豊富であると考えられます ( 4.5年の平均在任期間)。

Huakang Biomedical Holdings マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Chairman of the Board recently sold HK$815k worth of stock

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Recent updates

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023)

Huakang Biomedical Holdings Company Limited to Report First Half, 2024 Results on Aug 16, 2024

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24